<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Doxorubicin &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/doxorubicin/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Wed, 20 Oct 2021 06:35:25 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Doxorubicin &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国多柔比星市场研究报告，2016-2020年中国市场销售额CAGR高达38.60%</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguoduoroubixingshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Thu, 10 Jun 2021 08:19:10 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[Adriamycin]]></category>
		<category><![CDATA[Doxorubicin]]></category>
		<category><![CDATA[万乐药业]]></category>
		<category><![CDATA[乳腺癌]]></category>
		<category><![CDATA[化疗]]></category>
		<category><![CDATA[卵巢癌]]></category>
		<category><![CDATA[多柔比星]]></category>
		<category><![CDATA[多柔比星区域分析]]></category>
		<category><![CDATA[多柔比星市场份额]]></category>
		<category><![CDATA[多柔比星市场竞争]]></category>
		<category><![CDATA[多柔比星市场细分]]></category>
		<category><![CDATA[多柔比星市场规模]]></category>
		<category><![CDATA[多美素]]></category>
		<category><![CDATA[张江生物医药]]></category>
		<category><![CDATA[抗癌药]]></category>
		<category><![CDATA[抗肿瘤药]]></category>
		<category><![CDATA[普德药业]]></category>
		<category><![CDATA[欧意药业]]></category>
		<category><![CDATA[立幸]]></category>
		<category><![CDATA[蒽环类抗生素]]></category>
		<category><![CDATA[里葆多]]></category>
		<category><![CDATA[金远药业]]></category>
		<category><![CDATA[阿霉素]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24290</guid>

					<description><![CDATA[多柔比星又叫阿霉素，属于蒽环类抗生素，是一种化疗药物。CRI元哲的调研数据显示，中国市场多柔比星的销售额自2016-2020年逐年增加。2020年中国市场多柔比星销售额达到约10亿元人民币，2016-2020年CAGR高达38.60%。CRI元哲预计在2021-2025年随着乳腺癌患者的增多，多柔比星销售量会稳步提升。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
